INTRODUCTION {#s1}
============

Hypomyelinating leukodystrophies (HLDs) are neurodevelopmental disorders characterized by defective myelination in the central nervous system accompanied by developmental delay, spasticity, and intellectual disability ([@MCS004879COMC4]). HLDs are genetically heterogeneous disorders, and 17 types of HLDs have been identified by variations in different genes thus far. These genes include those that are directly related to myelination (i.e., *PLP1*, *GJC2*, *FAM126A*, and *TUBB4A*) but also genes for which the involvement in myelination is not yet characterized (e.g., *PYCR2*, *HIKESHI*, and *HSPD1*) ([@MCS004879COMC17]; [@MCS004879COMC21]; [@MCS004879COMC5]; [@MCS004879COMC6]; [@MCS004879COMC20]).

Among different types of HLDs, HLD4, also known as MitCHAP60 disease (MIM \#612233), is attributed to a biallelic pathogenic variant in the *HSPD1* gene and is inherited in an autosomal recessive manner ([@MCS004879COMC12]). HLD4 is a progressive neurodevelopmental disorder, presenting initially with central hypotonia, strabismus, and psychomotor delay. Patients develop acquired microcephaly, spasticity, and developmental regression. Seizures are also reported in some patients. Typically, the onset of the condition is within the first 3 months of life and is fatal within the first 2 decades. There is a wide range of reported intrafamilial and interfamilial phenotypic heterogeneity, particularly with respect to the degree of psychomotor impairment and the rate of neurologic and developmental deterioration. Brain magnetic resonance imaging (MRI) in these patients reveals diffuse hypomyelination, thin corpus callosum, thin brainstem, and varying degrees of ventricular enlargement. A subset of patients has markedly increased urinary secretion of ethylmalonic acid as well ([@MCS004879COMC12]; [@MCS004879COMC3]; [@MCS004879COMC11]).

The human *HSPD1* and *HSPE1* genes encode the essential mitochondrial HSP60 and HSP10 chaperones, respectively, which form a folding chamber to facilitate protein folding and assembly in the mitochondrial matrix space. Variations in *HSPD1* and *HSPE1* are implicated in the following neurological diseases ([Table 1](#MCS004879COMTB1){ref-type="table"}; [@MCS004879COMC3]): (i) homozygosity for the HSP60:p.Asp29Gly variation causes the fatal hypomyelination disorder (HLD4; MitCHAP60 disease; MIM \#612233) ([@MCS004879COMC12]; [@MCS004879COMC14]; [@MCS004879COMC11]), (ii) heterozygosity for the HSP60:p.Val98Ile variation causes spastic paraplegia (SPG13; MIM \#605280) ([@MCS004879COMC8]), (iii) heterozygosity for the HSP10:p.Leu73Phe variation causes a neurological and developmental disorder ([@MCS004879COMC2]), and (iv) heterozygosity for the HSP60:p.Leu47Val variation causes hypomyelination disorder ([@MCS004879COMC23]). In addition to these genetic variations, another molecular mechanism can lead to HSP10 chaperone deficiency, without involving a genetic alteration in the *HSPE1* gene. Specifically, [@MCS004879COMC19] demonstrated that newly synthesized HSP10 directly interacts with α-synuclein, forming α-synuclein aggregates that result in cytosolic trapping of HSP10. This prevents import of HSP10 into the mitochondrial matrix. The subsequent reduced levels of HSP10 in the mitochondrial matrix result in mitochondrial dysfunction. In agreement with this conclusion, Szego et al. showed that HSP10 overexpression delays α-synuclein pathology both in vitro and in vivo.

###### 

Genotype and clinical features of patients with *HSPD1* and *HSPE1* variations

  Disease association                                             Variations in *HSPD1* or *HSPE1*   Genotype                 Age at onset    Gender  Symptoms                                                                                                                                                                                      PolyPhen-2 prediction^a^   Growth in genetic complementation assay   *ACADS* polymorphism genotype    Urine ethylmalonic acid   Reference(s)
  --------------------------------------------------------------- ---------------------------------- ------------------------ -------------- -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ----------------------------------------- -------------------------------- ------------------------- ------------------------------------------------------------
  Hypomyelinating leukodystrophy 4 (HLD4;MitCHAP60; MIM 612233)   p.Asp29Gly c.\[86A \> G\]          Homozygous               3 mo              M     Progressive hypertonia and hyperreflexia, intermittent nystagmus, lack of head control, psychomotor developmental delay, no language, decreased social contact, progressive limb spasticity   Benign                     Slow, temperature-sensitive               c.\[625G \> A\]; \[625G \> A\]   Elevated                  [@MCS004879COMC12]; [@MCS004879COMC11]; [@MCS004879COMC14]
  Hereditary spastic paraplegia (SPG13; MIM 605280)               p.Val98Ile c.\[292G \> A\]         Heterozygous             40 yr             F     Severe functional handicaps, weakness of the lower limbs, retinopathy, ataxia, and mental retardation                                                                                         Possibly damaging          No growth                                 c.\[625G \> A\]; \[625=\]        N/A                       [@MCS004879COMC8]
  Neurological and developmental disorder                         HSP10:p.Leu73Phe c.\[217C \> T\]   Heterozygous (de novo)   3 mo              M     Infantile spasms, hypotonia, developmental delay, a slightly enlarged liver, nystagmus, macrocephaly                                                                                          Possibly damaging          N/A                                       c.\[625=\]; \[625=\]             Normal                    [@MCS004879COMC2]
  Hypomyelination                                                 p.Leu47Val c.\[139T \> G\]         Heterozygous (de novo)   18 mo             M     Diffuse hypomyelination, gait instability, mild ataxia, dysmature motor coordination                                                                                                          Probably damaging          No growth                                 c.\[625G \> A\]; \[625=\]        Elevated                  [@MCS004879COMC23]

\(M\) Male, (F) female, (N/A) not available.

^a^PolyPhen-2 has three levels of damage prediction, from most damaging to the least: probably damaging, possibly damaging, and benign.

Here, we report a case of a 7-yr-old patient, surprisingly carrying the same heterozygous de novo variant reported by Yamamoto et al. in the *HSPD1* gene, HSP60:p.Leu47Val, also presenting with an HLD phenotype. We share our functional protein assay results and discuss our findings in the context of the other phenotypes associated with *HSPD1* and *HSPE1* variations hitherto detected.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The patient is a 7-yr-old boy who was initially referred for evaluation because of speech and motor delays. He was born by vacuum-assisted vaginal delivery at 38 wk gestation to a G1P0 woman following an uncomplicated pregnancy. His early gross motor milestones fell within the normal range, but delayed milestones became apparent by 18 mo of age. He did not walk independently until 22 mo of age. Neurological evaluation at 24 mo of age revealed mild bilateral postural tremor in the upper extremities, mild ataxia, brisk deep tendon reflexes, and abnormal motor coordination. He was also clumsy and showed gait instability. He had no history of developmental regression or seizures. His brain MRI recorded at 36 mo of age showed diffuse/delayed hypomyelination of the cerebral and cerebellar white matter suggestive of underlying HLD ([Fig. 1](#MCS004879COMF1){ref-type="fig"}A--C). However, the patient had normal corpus callosum and cerebellar vermis at this age ([Fig. 1](#MCS004879COMF1){ref-type="fig"}D). Patient had mild postural tremor at 4 yr and 2 mo; reflexes were 2+ bilaterally in the patella and the Achilles' and 1+ bilaterally in the triceps. He was able to jump with two feet at 4 yr and 10 mo of age. Physical examination at 5 yr and 2 mo of age revealed normal growth parameters (height 85th percentile, weight 25--50th percentile, head circumference 75th percentile) and no dysmorphic features. No regression and no seizures were noted at this age. Examination at 7 yr and 9 mo revealed coordination and fatigue challenges, and motor development reaching to plateau. Urine metabolic screening detected increased excretion of ethylmalonic acid on three independent samples.

![MRI scans of the patient at 3 yr and 11 mo of age indicates hypomyelination (*A*) and (*B*) axial FLAIR images at different levels and (*C*) coronal T2 image showing diffuse high signal intensity of the cerebral and cerebellar white matter including the subcortical U fibers. Abnormal hyperintensity was most notable in the peritrigonal regions bilaterally. (*D*) Sagittal T1 image showing corpus callosum and cerebellar vermis are normal at this stage of the disease.](MCS004879Com_F1){#MCS004879COMF1}

The patient has not been on any medications. The family is of mixed Northern European, Italian, and French--Canadian descent. The family is nonconsanguineous, and its history is noncontributory.

Genomic Analyses {#s2b}
----------------

Trio whole-exome sequencing revealed a de novo heterozygous variant (c.139T \> G, p.Leu47Val) in the *HSPD1* gene. The variation was confirmed with Sanger sequencing. Subsequent multiplex ligation-dependent probe amplification (MLPA) analysis failed to detect any large deletions or duplications in the *HSPD1* gene. Sequencing analysis of the short-chain acyl-CoA dehydrogenase gene (*ACADS*) showed heterozygosity for the c.625G \> A common variant.

In Silico Analysis of the Variant Site {#s2c}
--------------------------------------

The HSP60 protein is highly conserved among species, and the sequence alignments of its first 100 amino acids, which contain the three disease-associated residues, confirms the complete sequence conservation of all known disease-associated variants from *Escherichia coli* to human ([Fig. 2](#MCS004879COMF2){ref-type="fig"}A). Moreover, the known disease-associated variants (Asp29, Leu47, and Val98) are closely localized and horizontally aligned in the HSP60 protein structure ([Fig. 2](#MCS004879COMF2){ref-type="fig"}B--D). The de novo *HSPD1* c.139T \> G, p.Leu47Val variant was not reported in the Genome Aggregation Database (gnomAD) v2.1.1 ([@MCS004879COMC10]).

![The de novo HSP60:p.Leu47Val variation occurs at a conserved residue, and disease-associated *HSPD1* variants are colocalized in the HSP60 protein structure. (*A*) Sequence alignment of the first 100 amino acids of the human HSP60 protein and its homologs illustrates the high sequence conservation among species. The patient variation occurs at the leucine residue at position 47 (red arrow), which is conserved from *E. coli* to human. Furthermore, other disease-causing variations occur at residues that are also conserved from *E. coli* to human (Asp29 and Val98). (*B*) The three disease-associated amino acids, Asp29, Leu47, and Val98, are shown on the seven-subunit HSP60 ribbon traces. Each color group highlights the three variant residues in their respective HSP60 subunit. ATP is shown as red sticks. (*C*) Disease-associated amino acids are localized not only in close proximity but also on the same horizontal plane. (*D*) The disease-associated variant residues are all in close proximity to the ATP-binding site; however, they are not in direct physical contact with the bound ATP molecule (marked as red sticks).](MCS004879Com_F2){#MCS004879COMF2}

Functional Studies with the *E. coli*--Based Genetic Complementation System {#s2d}
---------------------------------------------------------------------------

In this study, an *E. coli*--based in vivo complementation assay was performed to determine whether the HSP60:p.Leu47Val protein is functional. In a previous study we showed that the *groEL* and *groES* genes, the *E. coli* homologs of *HSPD1* and *HSPE1*, are essential for bacterial growth but can be replaced by the human HSP60 and HSP10 homologs expressed from a complementing plasmid ([@MCS004879COMC18]; [@MCS004879COMC12]). Thus, this system serves as a sensitive tool to check the in vivo function of various HSP60 variants and has been successfully used to determine the effects of patient variations on HSP60 function in vivo ([@MCS004879COMC8]). In these complementation studies, tetracycline resistance (Tet^R^) is used to identify those bacterial transductants that have exchanged DNA in the *groESgroEL* region, whereas chloramphenicol resistance (Cam^R^) is used to identify the subset that resulted in the simultaneous deletion of the entire *groESgroEL* operon. Thus, the frequency of Tet^R^Cam^R^ transductants versus Tet^R^-only transductants indicates the ability of the plasmid carrying the *HSP10*^+^ gene and either the HSP60 wild-type or HSP60:p.Leu47Val variant gene to substitute for the missing, essential *E. coli* GroES/GroEL function ([Fig. 3](#MCS004879COMF3){ref-type="fig"}A). Independent transformants carrying the HSP10^+^HSP60:p.Leu47Val plasmid were shown to express approximately equivalent HSP60 levels following isopropyl β-D-1-thiogalactopyranoside (IPTG) induction compared to transformants carrying the parental wild-type plasmid, as judged by total protein staining, suggesting that the variant protein is as stable as wild-type HSP60 in bacteria ([Fig. 3](#MCS004879COMF3){ref-type="fig"}B).

![*E. coli* functional study design and expression of wild-type HSP60 and the HSP60:p.Leu47Val variant. (*A*) Transduction experiment design to test complementation of *E. coli* GroEL with human HSP60. DNA transducing fragment carrying tetracycline resistance (Tet^R^) and chloramphenicol resistance (Cam^R^) is used to replace the endogenous *groESgroEL* operon in the presence of a complementing plasmid expressing HSP10^+^ and either HSP60^+^ or HSP60:p.Leu47Val. The red squiggles indicate potential recombination crossover pathways. The low frequency of deletion of the *groESgroEL* operon in the presence of the HSP10^+^HSP60: p.Leu47Val plasmid indicates the dysfunction of the disease-associated variant. (*B*) The wild-type HSP60 and the p.Leu47Val variant are expressed in *E. coli* cells. The arrow indicates HSP60 protein. The star indicates Cam^R^ protein expressed by the plasmid. "WT" is lysate from *E. coli* expressing wild-type HSP60. "p.Leu47Val Variant" are lysates from different clones expressing the HSP60:p.Leu47Val variant. HSP10 is not discernible on this gel.](MCS004879Com_F3){#MCS004879COMF3}

The high linkage found between the Tet^R^ and Cam^R^ markers demonstrates that the plasmid pHSP10^+^HSP60^+^ encoding the wild-type HSP10 and HSP60 genes is able to substitute for *E. coli* GroES/GroEL function. In contrast, we found that the plasmid pHSP10^+^HSP60: p.Leu47Val does not complement the deletion of *E. coli groESgroEL* at 37°C ([Table 2](#MCS004879COMTB2){ref-type="table"}). The 11 unexpected Cam^R^ transductants isolated were shown to express the resident *E. coli* GroEL using functional tests and thus did not represent true *groEL* deletion variants. In conclusion, our results clearly demonstrate that wild-type HSP60, but not the HSP60: p.Leu47Val variant, can support the growth of *E. coli* cells.

###### 

Results of the complementation study show that the replacement of the *E. coli groESgroEL* operon by plasmid-encoded Hsp10^+^Hsp60^:^p.Leu47Val does not complement growth of *E. coli*

  Plasmid                     Tet^R^   Cam^R^    Linkage (%)
  --------------------------- -------- --------- -------------
  pHsp10^+^Hsp60^+^           149      133       89^b^
  pHsp10^+^Hsp60:p.Leu47Val   312        11^a^      3.5

A high linkage score indicates the *groESgroEL* operon can be readily deleted from the chromosome because the complementing plasmid encodes a functional protein.

^a^The 11 Cam^R^ transductants were further tested and shown to be sensitive to bacteriophage T4 infection, indicating that they still possess GroEL function and most likely represent rare aberrant recombination/duplication events.

^b^Because of the use of T4 as the transducing phage, the expected linkage between the Tet^R^ and Cam^R^ genes is higher than that reported by [@MCS004879COMC8].

Quantification of Wild-Type and Variant HSP60 Peptide Levels {#s2e}
------------------------------------------------------------

To assess whether the HSP60:p.Leu47Val variant protein was stably expressed in patient cells, we performed mass spectrometry analyses to determine the relative amounts of wild-type HSP60 and HSP60:p.Leu47Val variant protein present in the patient\'s fibroblasts. We detected a total of 29 different peptides ([Fig. 4](#MCS004879COMF4){ref-type="fig"}A), including the wild-type and variant peptide ([Fig. 4](#MCS004879COMF4){ref-type="fig"}B), of the HSP60 protein. Calculations based on our mass spectrometry data indicated similar amounts of variant and HSP60 wild-type proteins in the patient\'s fibroblasts ([Fig. 4](#MCS004879COMF4){ref-type="fig"}C). As the wild-type HSP60 protein constitutes 100% in the control cells, the percentage of the HSP60:p.Leu47Val protein in the patient cells is ∼50%, thus demonstrating that the mutant HSP60:p.Leu47Val protein is as stable as wild-type HSP60.

![Detection and quantification of wild-type and variant HSP60 peptide levels by mass spectrometry demonstrate that the variant protein is present, suggesting that the mutation is causing a dominant negative effect on HSP60 function. The experiment was performed on fibroblast cultures from three nonrelated healthy control individuals and three independent cultivation samples from the patient. (*A*) The HSP60 peptide sequences detected and quantified by mass spectrometry are highlighted in yellow on the human HSP60 amino acid sequence. The peptide sequence detected containing the patient variation site (p.Leu47Val) is marked in red. (*B*) Variant peptide peak graphs extracted from the ion chromatogram of the mass spectrometry analysis show the detection of the variant peptide only in the patient\'s samples. (*C*) Calculation of the relative fraction of wild-type HSP60 and the p.Leu47Val variant based on mass spectrometry analyses (see Materials and Methods) reveals that the variant protein constitutes ∼50% of the total HSP60 protein in the patient fibroblasts.](MCS004879Com_F4){#MCS004879COMF4}

DISCUSSION {#s3}
==========

The advancement of next-generation sequencing techniques has improved the detection of rare disease-causing genetic variations in the diagnosis of previously undiagnosed patients. These advancements considerably speed up the discovery of de novo mutations and mutational hotspots in the human genome. Detection of the same de novo variation in multiple patients with the same disease phenotypes contributes to the confirmation of the disease-causing nature of gene variations and in-depth functional studies of the variant proteins expand our knowledge on molecular functions ([@MCS004879COMC1]).

As reported before, different disease-causing variations in the *HSPD1* and *HSPE1* genes, which respectively encode the mitochondrial HSP60 and HSP10 chaperones, have been found to result in a spectrum of neurodevelopmental diseases with different severities (summarized in [Table 1](#MCS004879COMTB1){ref-type="table"}) ([@MCS004879COMC3]). Here, we propose a possible novel autosomal dominant mechanism for HLD4 and suggest that a subset of autosomal dominant pathogenic variants in the *HSPD1* gene produces an HLD phenotype. We based this mechanism on our investigations of a case of the 7-yr-old patient that presented with a brain MRI finding consistent with HLD and a heterozygous p.Leu47Val de novo variation in the *HSPD1* gene, together with the case previously reported ([@MCS004879COMC23]).

To evaluate the disease-causing nature of the p.Leu47Val variation, we performed in silico analyses and in vivo functional assays. The sequence alignment of the human HSP60 protein and its homologs shows the strict conservation of Leu47, together with the other disease-associated amino acid residues---Asp29 and Val98---from *E. coli* to humans ([Fig. 2](#MCS004879COMF2){ref-type="fig"}A). Our structural analysis suggests that these amino acids could be involved in stabilization of the seven-subunit HSP60 structure. Indeed, a recent publication has shown that the p.Asp29Gly and p.Val98Ile variations interfere with functional conformational changes in the HSP60 chaperone complex ([@MCS004879COMC22]). These disease-associated amino acids are located in close proximity to each other and the ATP-binding domain, yet are not directly in contact with the bound ATP ([Fig. 2](#MCS004879COMF2){ref-type="fig"}B--D). This further supports the possibility that replacement of the linear carbon side chain of leucine with the β-branched valine in this densely packed part of the HSP60 structure may also disturb transmission of the conformational changes triggered by ATP hydrolysis, and thus impair protein function.

Urine metabolic screening detected increased excretion of ethylmalonic acid, which is an indicator of short chain acyl-CoA dehydrogenase (SCAD, *ACADS*) deficiency, an inborn error of mitochondrial fatty acid metabolism. Elevated urine ethylmalonic acid has also been observed in patients in whom homozygosity for the polymorphic c.624G \> A variation was found as the only variation in the *ACADS* gene ([@MCS004879COMC7]; [@MCS004879COMC16]). Presence of intermittent increase of urinary ethylmalonic acid excretion has been described in patients with HLD4 ([@MCS004879COMC12]; [@MCS004879COMC11]). Earlier studies have shown functional interaction of SCAD with the HSP60 chaperone ([@MCS004879COMC15]), and therefore elevated levels of ethylmalonic acid, as seen in the current patient, may be the result of the heterozygosity for the c.625G \> A common variant in the *ACADS* gene, in connection with the impaired HSP60 function.

Discrepancies between in silico analysis and in vivo functional assays for HSP60 variants have shown the importance of evaluating the activity of the HSP60/HSP10 complex in each case ([@MCS004879COMC3]). Here we used both an *E. coli*--based genetic complementation system and patient\'s fibroblasts for in vivo functional analyses. The genetic complementation system showed abolished bacterial cell growth and a decreased linkage score for the HSP60:p.Leu47Val variant, indicating its failure to complement the deletion of the *E. coli groESgroEL* operon ([Table 2](#MCS004879COMTB2){ref-type="table"}), demonstrating a loss of protein function. Moreover, in the patient\'s fibroblasts we detected a 1:1 ratio of wild-type to variant peptide, indicating that it is stable ([Fig. 4](#MCS004879COMF4){ref-type="fig"}C). In the previous report of this variation, Yamamato et al. discusses the possibility of compound heterozygosity for the *HSPD1* variant. Detection of both the variant and the wild-type peptides in equal amounts in patient\'s fibroblasts excludes the possibility of compound heterozygosity through variations in the noncoding regions of the wild-type allele that might affect its expression. Taken together, our functional results are consistent with the conclusion that the HSP60:p.Leu47Val variant exerts an autosomal dominant disease mechanism.

In summary, this case study reveals a de novo variant in the *HSPD1* gene with an autosomal dominant disease mechanism. As such, it is important to consider the possibility that other heterozygous de novo variants in the *HSPD1* gene may exist, resulting in neurodevelopmental disorder manifestations such as HLD. The presence of the same de novo variation in two different patients with similar clinical phenotypes might suggest that the p.Leu47Val variant is the consequence of a mutational hotspot in the *HSPD1* gene. However, the mutated base is not in a CpG site that would increase susceptibility to mutation. It is likely that variation of this amino acid comes to clinical attention because this position in the protein is especially crucial. The basis for the mechanistic role of *HSPD1* in myelination is yet to be understood. These developments reveal the therapeutic potential of HSP60-targeting compounds and contribute to the continuing interest of developing small molecules to modulate HSP60 function in a variety of diseases ([@MCS004879COMC13]). Finally, this study further underlines the potential of whole-exome sequencing in the diagnosis of rare diseases, and the necessity of performing functional assays in order to confirm disease-causing potential of de novo variants.

METHODS {#s4}
=======

Genomic Analyses {#s4a}
----------------

Whole-exome sequencing was performed by Centogene AG, and 100% coverage for coding regions of the *HSPD1* gene was reported by the company ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004879/-/DC1)). Sanger sequencing confirmation was performed on genomic DNA isolated from the patient\'s fibroblasts and blood samples from the patient and his parents. Exon 2 of the *HSPD1* gene was amplified by polymerase chain reaction (PCR), and bidirectional sequencing of the PCR product was performed with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) and using an Applied Biosystems 3500 Dx Genetic Analyzer.

*E. coli* Functional Studies {#s4b}
----------------------------

*E. coli* cells were grown to exponential phase in LB medium at 37°C; plasmid-encoded gene expression was induced by the addition of 4 mM IPTG and grown for an additional 2 h. Equal volumes of cell lysate were resolved on a Novex NuPAGE 4%--12% Bis-Tris/MES Protein Gel (Invitrogen) and stained with Coomassie blue for total protein detection. Independent transformants carrying Hsp60:p.Leu47Val-coding plasmids induced approximately equivalent HSP60 levels following IPTG induction as the parental wild-type plasmid, as judged by protein staining ([Fig. 3](#MCS004879COMF3){ref-type="fig"}B). The transduction procedure was essentially as described by [@MCS004879COMC8] except that bacteriophage T4 was used to prepare the lysate on the donor strain AR1893, in which the essential *groESgroEL* operon is deleted and replaced by the Cam^R^ gene on the bacterial chromosome. A Tet^R^ gene is inserted downstream as an outside marker. These cells are kept alive by the presence of a plasmid expressing the wild-type *E. coli groESgroEL* operon. Wild-type *E. coli* cells transformed with a kanamycin-resistant (Kan^R^) plasmid encoding HSP10^+^ and either HSP60^+^ or HSP60:p.Leu47Val were infected with the T4 donor lysate. The resulting transductants were selected first for Tet^R^, followed by screening for the simultaneous acquisition of the nearby Cam^R^ marker. Our previous work showed that pHSP10^+^HSP60^+^ supports deletion of *groESgroEL*, resulting in transductants that are both Tet^R^ and Cam^R^. The red squiggles in [Figure 3](#MCS004879COMF3){ref-type="fig"}A indicate potential recombination crossover pathways. DNA sequencing of the plasmids confirmed that no other mutations were present in the insert.

Quantification of Wild-Type and Variant HSP60 Peptide Levels {#s4c}
------------------------------------------------------------

Human dermal fibroblasts from the patient, as well as three nonrelated healthy individuals as controls, were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum, 29 mg/mL of L-glutamine (Sigma-Aldrich), and 0.1% penicillin/streptomycin (Sigma-Aldrich) at 37°C and 5% CO~2~ in *Mycoplasma sp.*-free conditions. Fibroblast pellets were dissolved in 0.35 M Tris-HCl pH 6.8, 0.60 M dithiothreitol, and 10% (w/v) sodium dodecyl sulfate and ultrasonicated (Branson Sonifier 250, Branson Ultrasonics Corp) at 30% duty cycle for three cycles of five pulses, with 1 min of ice incubation between each cycle. Lysates were centrifuged at 14,000*g* for 30 min at 4°C, and 30 µg of extracted proteins were separated by polyacrylamide gel electrophoresis on a BioRad AnykD Criterion TGX protein gel and stained with Coomassie blue. Each sample was excised from the stained gel and samples were further prepared for nano Liquid-Chromatography coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) as described previously ([@MCS004879COMC9]). Relative amounts of wild-type and variant HSP60 proteins in control and patient fibroblasts were quantified with mass spectrometry. HSP60 peptides were identified and quantitated using Proteome Discoverer 2.2 and MaxQuant 1.5.3.30 software. The fraction of wild-type and variant HSP60 protein in the control and patient samples was calculated by quantifying the ratio of the area under the curve of the wild-type peptide containing the mutation site to the average areas under the curve of 29 HSP60 peptides ([Fig. 4](#MCS004879COMF4){ref-type="fig"}).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The *HSPD1* variant (c.139T \> G, p.Leu47Val) was submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV001164600. Authors declare no further data to be deposited, as consent for publicly reporting the full exome sequencing data was not obtained.
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